Skip to main content

Ingeniería y desarrollo de un nuevo “pulmobioterapéutico” para el tratamiento del cáncer de pulmón

PTQ2020-011048

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Torres Quevedo
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre PULMOBIOTICS SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engineering Mycoplasma pneumoniae to bypass the association with Guillain-Barré syndrome

  • Broto, Alicia|||0000-0002-3275-8524
  • Piñero-Lambea, Carlos|||0000-0002-5263-3702
  • Segura-Morales, Carolina|||0000-0002-1746-6865
  • Tio-Gillen, Anne P.
  • Unger, Wendy W.J.
  • Burgos Castellanos, Raül|||0000-0002-4452-9235
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Miravet-Verde, Samuel
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Casas, Josefina|||0000-0002-7926-5209
  • Huizinga, Ruth
  • Lluch-Senar, Maria|||0000-0001-7568-4353
  • Serrano, Luis|||0000-0002-5276-1392
A non-pathogenic Mycoplasma pneumoniae -based chassis is leading the development of live biotherapeutic products (LBPs) for respiratory diseases. However, reports connecting Guillain-Barré syndrome (GBS) cases to prior M. pneumoniae infections represent a concern for exploiting such a chassis. Galactolipids, especially galactocerebroside (GalCer), are considered the most likely M. pneumoniae antigens triggering autoimmune responses associated with GBS development. In this work, we generated different strains lacking genes involved in galactolipids biosynthesis. Glycolipid profiling of the strains demonstrated that some mutants show a complete lack of galactolipids. Cross-reactivity assays with sera from GBS patients with prior M. pneumoniae infection showed that certain engineered strains exhibit reduced antibody recognition. However, correlation analyses of these results with the glycolipid profile of the engineered strains suggest that other factors different from GalCer contribute to sera recognition, including total ceramide levels, dihexosylceramide (DHCer), and diglycosyldiacylglycerol (DGDAG). Finally, we discuss the best candidate strains as potential GBS-free Mycoplasma chassis.